Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged biologics · clear
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the last five years, from July 1, 2017, through June 30, 2022. Previously, on Patexia 148 , we analyzed the…
In a recent development with the ongoing complex litigation involving Janssen Biotech’s arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar,(1) Celltrion’s partner Pfizer has filed a suit against Janssen’s…
Written by Robert J. Hilton, Ph.D. and Jing Liu, Ph.D. On January 13, 2017, the Supreme Court granted certiorari in Amgen v. Sandoz, 794. f. 3d 1347 (Fed. Cir. 2015) and Sandoz v. Amgen, 773 f. 3d 1274 (Fed. Cir. 2014), appealed from the Federal Circuit.…
